ArticleJournal of the American Chemical Society2025
Responsive Organoselenium Dendritic Polymers: From Monodisperse Dendrimers to Self-Assembled Micelles for Advanced Therapeutic Applications.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unraveling the Physicochemical Landscape of Organoselenium Compounds in Nanocarrier Systems.Chemical record (New York, N.Y.) · 2026Review
- Strong Antiproliferative Activity Observed in Hammett-Guided Electronic Modulation of GPx-Mimetic Pathways in Aryl Selenoureas.International journal of molecular sciences · 2026Article
- Mitochondria-targeting organoselenium theranostic radioprotectors for simultaneous treatment and imaging of radiation-induced liver injury.Theranostics · 2026Article
- Advancements in Tumor-Targeted Nanoparticles: Design Strategies and Multifunctional Therapeutic Approaches.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium (Se) is a highly biologically active element, and its organic derivatives have attracted growing interest for their promising chemotherapeutic potential, largely due to their redox-modulating activity, which selectively affects cancer cells with high levels of reactive oxygen species (ROS). However, their high reactivity and susceptibility to spontaneous degradation limit their biomedical application. To harness their potential in the realm of nanomedicine, we present a new generation of therapeutically promising polymers that combine Se with 2,2-bis(methylol)propionic acid (bis-MPA)-based dendritic polymers, chosen for their high chemical versatility, low toxicity, and excellent biodegradability. Most examples in the literature about dendritic polymers feature dormant dendritic skeletons with active functional groups expressed only on their periphery, which severely limits their functional scope. In this work, monodisperse dendrimers and linear-dendritic (LD) polymers up to the third generation were developed, with the latter capable of self-assembling into dendritic micelles (∼20 nm). These systems feature Se at the dendritic core or peripheral branches in the form of monoselenide or diselenide bridges. Selenium incorporation demonstrated excellent compatibility with two key polyester synthetic approaches: anhydride chemistry and fluoride-promoted esterification (FPE). Both monoselenide and diselenide linkages introduced degradability and dynamic behavior in dendrimers and dendritic micelles. However, their biological activities differed significantly. Diselenide-containing dendrimers exhibited great anticancer potential against breast cancer cell lines, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.